newsfilter
← Latest News
GlobeNewswire·

Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022

--Updated Data on Phase 1/2 Trial Evaluating PORT-2 Presented at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting-- --Clinical Collaboration Agreement Entered into with Merck for Evaluation of PORT-2